Interleukin-6 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension
-
- Yoshiaki Furuya
- Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi,Shinjuku-ku, Tokyo 160-8582, Japan
-
- Toru Satoh
- Department of Cardiology, Kyorin University Graduate School of Medicine, Mitaka, Tokyo 181-8611, Japan
-
- Masataka Kuwana
- Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi,Shinjuku-ku, Tokyo 160-8582, Japan
書誌事項
- 公開日
- 2010
- 権利情報
-
- http://creativecommons.org/licenses/by/3.0/
- DOI
-
- 10.1155/2010/720305
- 公開者
- Wiley
この論文をさがす
説明
<jats:p>Interleukin-6 (IL-6) is a pleiotropic cytokine with a wide range of biologic activities in immune regulation, hematopoiesis, inflammation, and oncogenesis. Recent accumulating evidence indicates a pathologic role for IL-6 in promoting proliferation of both smooth muscle and endothelial cells in the pulmonary arterioles, resulting in development of pulmonary arterial hypertension (PAH). Here, we describe a patient with mixed connective tissue disease and severe, refractory PAH. Her functional activity and hemodynamic parameters dramatically responded to tocilizumab, a humanized monoclonal antibody to human IL-6 receptor, which was aimed at treating multicentric Castleman's disease. It appears that IL-6 blockade may hold promise as an adjunct drug in treatment of PAH in idiopathic form as well as in association with connective tissue disease.</jats:p>
収録刊行物
-
- International Journal of Rheumatology
-
International Journal of Rheumatology 2010 1-8, 2010
Wiley